Background: US national guidelines call for cost-conscious practices including the selection of antiretroviral therapy.
Introduction
Antiretroviral therapy (ART) has improved morbidity and mortality for persons living with HIV (PLWH) [1] . Currently, there are many effective regimens for treatment-naïve PLWH [2] . In addition to efficacy, antiretroviral durability, defined as the time from regimen initiation to discontinuation, has been associated with improved clinical outcomes [3] . Durability was adopted early in the ARTera as an indirect measure of effectiveness and tolerability.
Perceptions of ART durability and preferred regimens are ever changing. Efavirenz has fallen from favor following reports of increased suicidality in clinical trials [4, 5] . Similarly, rilpivirine, the backbone of a once preferred single-tablet regimen, is now known to have limited efficacy in those with a high HIV RNA viral load. Owing to these limitations and the availability of alternative, tolerable options, efavirenz (Atripla) and rilpivirine (Complera) are no longer recommended as first-line therapy for treatment-naive PLWH [6] . Both were downgraded to the 'alternative' category by the 2015 Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Of note, the striking number of efavirenz-related suicidality events reported in mostly open-label clinical trials was not reproduced in large observational studies [7, 8] . With increasing ART options and an evolving treatment landscape, understanding comparative effectiveness is essential.
ART is cost-effective, but it is costly and constitutes over 70% of comprehensive HIV healthcare expenses [9, 10] . Recently, the DHHS asked providers to educate themselves on antiretroviral regimen costs and generic antiretroviral availability [6] . Nonetheless, the five regimens recommended for treatment-naive patients, according to the DHHS panel, include the most expensive, least cost-effective options [6, 11, 12] . Alternatively, Atripla and Complera, both downgraded to 'alternative' options, have been shown to be the most cost-effective options [12, 13] . Although there is a growing demand for cost-conscious HIV care, there is little data on relative cost-effectiveness of contemporary antiretroviral regimens, and current guidelines do not incorporate cost considerations in the selection of preferred treatment regimens. We, therefore, analyzed the cost and utility of contemporary antiretroviral regimens in a real-world, clinical setting.
Methods
This is a cost-effectiveness analysis of five antiretroviral regimens incorporating durability and monthly medication costs from the clinic perspective. Although durability is not widely used in cost-effectiveness analyses, it is used often in comparative effectiveness research of HIV treatment [14, 15] . Regimens and durability data were obtained from an observational cohort at the 1917 Clinic, the University of Alabama at Birmingham (UAB)affiliated HIV clinic serving more than 3000 PLWH. The UAB 1917 Clinic Cohort database was queried for treatment-naïve patients initiating antiretrovirals (!3 drugs) for at least 14 days between 1 January 2007 and 31 December 2012. Pregnant patients were excluded. A total of 546 patients were eligible, but analysis was restricted to patients initiating one of the following: emtricitabine and tenofovir in combination with efavirenz, with raltegravir, with ritonavir and darunavir, with ritonavir and atazanavir, or with rilpivirine as they represented 90% of prescriptions to treatment-naïve patients during the study period. The study was approved by the UAB Institutional Review Board.
Effectiveness
Durability was defined as time from ART regimen initiation to discontinuation, regardless of reason for discontinuation. Any change in ART lasting more than 14 days was considered discontinuation. Switching from individual drugs to a fixed dose combination of the same constituent drugs was not considered discontinued. Patients were censored after their last contact with the clinic, death, or end of follow-up period (December 2014), whichever came first. If a patient was lost to follow-up prior to regimen discontinuation, their regimen was considered discontinued 6 months from their last HIV provider visit, as typically patients are given six refills per visit.
Antiretroviral cost
The cost of a 30-day supply of each regimen was calculated using the average 340b pricing provided by four national wholesale pharmacies [16] . The 340b Drug Discount Program, a federal program for those serving vulnerable and low-income patients, requires manufacturers provide reduced prices to eligible healthcare institutions [16] . The 1917 Clinic is eligible for 340b pricing.
Statistical analysis
Median durability (months) was obtained from the Kaplan-Meier survival curves. The incremental costeffectiveness ratio (ICER) of each regimen was calculated by comparing each regimen to the next most costly regimen. An ideal regimen will have a low ICER: for a minimal additional cost it provides greater durability.
Sensitivity analysis
Several sensitivity analyses were performed. First, cost inputs were varied using a regional 340b vendor price, average wholesale price (AWP), and market price [6] . Then, durability was adjusted for each regimen using mean months of durability AE1 SD. Third, durability was adjusted for those lost to follow-up (N ¼ 117): date of loss to follow-up was considered the discontinuation date and date of loss to follow-up plus 3 months was considered discontinuation date. An additional analysis excluded those lost to follow-up.
Results
Overall, 491 patients met inclusion criteria. Mean age was 36 years (SD ¼ 11 years), 83% were men and 61% were African-American. Median relative durability was lowest for ritonavir-boosted atazanavir (31.9 months), followed by rilpivirine (36.3 months) and efavirenz (40.1 months), whereas greatest for ritonavir-boosted darunavir and raltegravir (47.8 months; Table 1 ). Although regimen costs varied by price index, efavirenz and rilpivirinebased regimens were consistently the least expensive (Tables 1 and 2) .
Base case analysis ICER was first calculated using the base case: median durability of all patients and average 340b pricing. All regimens were dominated, meaning less durable and more costly, when compared with the efavirenz and raltegravirbased regimens. This pattern was consistent regardless of the pricing index. The incremental cost of raltegravir per additional month of durability relative to efavirenz was $47 with a range of $46-$56 ( Table 2) depending on price index. When using market price and AWP, the rilpivirine-based regimen was also cost-effective. The incremental cost of efavirenz per additional month of durability relative to rilpivirine was $6 and $23 based on market price (Table 2) and AWP, respectively.
Sensitivity analyses
When durability decreased (À1 SD) in sensitivity analysis, there was more variability in ICER by price index, but atazanavir and darunavir were consistently dominated. As durability increased (þ1 SD), efavirenz and rilpivirinebased regimens were the only consistently valuable options. When varying the date of discontinuation for patients lost to follow-up (0, 3 months as described above) and when excluding those lost to follow-up, all regimens were dominated other than efavirenz and raltegravir; Rilpivirine became a valuable option when using market price ( Table 2 ) and AWP. When excluding those lost to follow-up, the incremental cost per month of durability for raltegravir relative to efavirenz ranged from $177 to $216. The incremental cost of efavirenz per additional month of durability relative to rilpivirine was $2 and $7, using market price and AWP, respectively.
Discussion
With the release of the 2015 DHHS Guidelines came significant changes to first-line HIV treatment recommendations: Atripla and Complera lost their position among preferred regimens and were replaced by newer, more expensive options including dolutegravir, raltegravir, Triumeq, and Stribild. Newly recommended regimens range from $100 to $900 more per patient per month when compared with Atripla and Complera [6] . The price differences are challenging to reconcile; these same guidelines include a section on cost considerations, which states that providers should incorporate costs into decision-making and prescribing practices.
Our study incorporates the durability and cost of five contemporary ART regimens. Two of these, darunavir and raltegravir-based regimens, are currently recommended, but the efavirenz (Atripla), rilpivirine (Complera), and atazanavir-based regimens are not. All other regimens were consistently dominated, meaning less durable and more costly, relative to the efavirenz and raltegravir-based regimens. The rilpivirine and efavirenzbased regimens were consistently least expensive across all pricing indices, but the rilpivirine was only a costeffective option when market price and AWP pricing data were used. Despite widely reported central nervous system (CNS) toxicities, the efavirenz-based regimen was quite durable in our population (median 40.1 months) [4, 17, 18] . This longevity and inexpensive price ($710.64) made it one of the most cost-effective options. Only raltegravir and darunavir-based regimens offered greater durability (47.8 months). Given the higher price of the raltegravir-based regimen ($1075.03), the incremental cost was $47 per additional month of therapy relative to the efavirenz-based regimen. In other words, selection of raltegravir over efavirenz for initial treatment will provide
Cost considerations in the current antiretroviral era Eaton et al. 2217 Table 1 . Prescribing patterns, durability, regional 340b pricing, and average wholesale price for five common regimens. Percentage of those receiving the specific treatment regimen out of 546 eligible patients. b Regional 340b price is the actual acquisition cost charged to our clinic for the purchase of specific regimens. M Note: The 75th percentile could not be estimated as the 'event' percentage did not reach 75%.
roughly 1 more month of durability at an additional cost of $47 per patient per month over the course of treatment. If the raltegravir, darunavir, or newer dolutegravir-based regimens are consistently chosen over efavirenz following treatment guidelines, the HIV drug-related costs will increase tremendously with potentially limited benefit.
Notably, the raltegravir-based regimen is the only recommended regimen that is twice daily as opposed to once daily. In our analysis, raltegravir was more durable than all once daily regimens except darunavir. It is also less expensive than the dolutegravir and darunavir-based regimens, both of which are recommended as first line.
Whether most providers select one of these once daily regimens over raltegravir, despite them being more costly options, remains to be seen.
This study was conducted in a single academic center with a moderate sample size; however, the findings were reproduced in multiple sensitivity analyses. Durability has not been used in cost-effectiveness analyses of antiretroviral regimens but is a commonly used comparative effectiveness metric for antiretroviral therapy. It is reassuring that the relative durability of regimens in our study is consistent with published data [19] . An ideal assessment would evaluate utility using a more standard metric than durability, such as the quality-adjusted life year, and would incorporate the cost of all recommended regimens (dolutegravir and Triumeq), but data are limited because of their recent release. Costs vary widely across vendors, payers, and calendar year. Trends in relative costeffectiveness of each of the five regimens, however, were unchanged regardless of pricing indices.
In conclusion, although Atripla and Complera are not ideal for all patients, they likely still have a role in the current HIV treatment era. Following changes in treatment guidelines, however, many clinicians have abandoned both regimens in treatment-naive patients. Our study demonstrates that efavirenz is durable and cost-effective. The raltegravir-based regimen was the only additional cost-effective option, offering greater durability at an additional cost of $47/month of therapy. Further antiretroviral cost-effectiveness analysis using standard measures, such as quality-adjusted life year, are essential and should be incorporated into guidelines to optimize care and control rising healthcare costs. The association between efavirenz and CNS toxicity, which was not evaluated in this study, should be further studied in observational settings before we discard this treatment altogether. ICER, incremental cost-effectiveness ratio is calculated by comparing the difference in the cost divided by the difference in effect dominated means that a treatment is less durable and more costly than the regimen in the preceding row. a Average 340b price is the average of four national wholesale pharmacies who provide discounted drugs via the 340b Prime Vendor Program.
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